Clinical Trial Update: Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

View source ↗

Summary

A long-term follow-up study of male adults with Hemophilia B previously treated with etranacogene dezaparvovec (CSL222) is enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Hemgenix (etranacogene dezaparvovec)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia B | Status: ENROLLING_BY_INVITATION